MA54458A - Formes cristallines et formes salines d'un inhibiteur de kinase - Google Patents

Formes cristallines et formes salines d'un inhibiteur de kinase

Info

Publication number
MA54458A
MA54458A MA054458A MA54458A MA54458A MA 54458 A MA54458 A MA 54458A MA 054458 A MA054458 A MA 054458A MA 54458 A MA54458 A MA 54458A MA 54458 A MA54458 A MA 54458A
Authority
MA
Morocco
Prior art keywords
crystalline
kinase inhibitor
salt forms
salt
forms
Prior art date
Application number
MA054458A
Other languages
English (en)
Other versions
MA54458B1 (fr
Inventor
Melanie Janelle Bevill
Frenel Demorin
Courtney S Johnson
Stephan D Parent
Khalid Shah
Sagar Shakya
Peter Wong
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA54458A publication Critical patent/MA54458A/fr
Publication of MA54458B1 publication Critical patent/MA54458B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA54458A 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase MA54458B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US201962856469P 2019-06-03 2019-06-03
EP19836338.4A EP3894012B1 (fr) 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase
PCT/US2019/065972 WO2020123800A1 (fr) 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase

Publications (2)

Publication Number Publication Date
MA54458A true MA54458A (fr) 2021-10-20
MA54458B1 MA54458B1 (fr) 2025-09-30

Family

ID=69160358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54458A MA54458B1 (fr) 2018-12-13 2019-12-12 Formes cristallines et formes salines d'un inhibiteur de kinase

Country Status (33)

Country Link
US (2) US12017995B2 (fr)
EP (2) EP4631505A3 (fr)
JP (3) JP7509779B2 (fr)
KR (2) KR102828472B1 (fr)
CN (1) CN113329790A (fr)
AU (2) AU2019395419B2 (fr)
BR (1) BR112021011333A2 (fr)
CA (1) CA3122840A1 (fr)
CL (1) CL2021001537A1 (fr)
CO (1) CO2021007613A2 (fr)
CR (1) CR20210375A (fr)
DK (1) DK3894012T3 (fr)
ES (1) ES3052838T3 (fr)
FI (1) FI3894012T3 (fr)
GE (1) GEP20247596B (fr)
HR (1) HRP20251122T1 (fr)
HU (1) HUE072868T2 (fr)
IL (2) IL320433A (fr)
LT (1) LT3894012T (fr)
MA (1) MA54458B1 (fr)
MD (1) MD3894012T2 (fr)
MX (1) MX2021006951A (fr)
PE (1) PE20211757A1 (fr)
PH (1) PH12021551356A1 (fr)
PL (1) PL3894012T3 (fr)
PT (1) PT3894012T (fr)
RS (1) RS67216B1 (fr)
SG (1) SG11202105949RA (fr)
SI (1) SI3894012T1 (fr)
SM (1) SMT202500346T1 (fr)
TW (1) TWI852963B (fr)
WO (1) WO2020123800A1 (fr)
ZA (1) ZA202103844B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
MX2021014773A (es) * 2019-06-03 2022-01-18 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas.
CN115461328B (zh) * 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
IL300151A (en) * 2020-07-31 2023-03-01 Exelixis Inc Combinations for cancer treatment
JP2023548855A (ja) * 2020-11-05 2023-11-21 エグゼリクシス， インコーポレイテッド キナーゼ阻害剤の医薬組成物
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
US20250368606A1 (en) 2021-12-22 2025-12-04 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (fr) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(méthyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phényl]-N'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide pour le traitement du cancer
CA2604238C (fr) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
ES2599458T3 (es) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compuestos y métodos de uso
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MA48776A (fr) 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
CN117402114A (zh) * 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
MX2021014773A (es) * 2019-06-03 2022-01-18 Exelixis Inc Formas de sales cristalinas de un inhibidor de cinasas.

Also Published As

Publication number Publication date
MD3894012T2 (ro) 2025-11-30
CN113329790A (zh) 2021-08-31
JP2022512399A (ja) 2022-02-03
EP3894012B1 (fr) 2025-06-18
CA3122840A1 (fr) 2020-06-18
CO2021007613A2 (es) 2021-06-21
SI3894012T1 (sl) 2025-10-30
HUE072868T2 (hu) 2025-12-28
BR112021011333A2 (pt) 2021-08-31
EP3894012A1 (fr) 2021-10-20
SMT202500346T1 (it) 2025-11-10
ES3052838T3 (en) 2026-01-15
WO2020123800A1 (fr) 2020-06-18
JP7509779B2 (ja) 2024-07-02
JP7783870B2 (ja) 2025-12-10
MX2021006951A (es) 2021-07-15
PL3894012T4 (pl) 2026-01-05
HRP20251122T1 (hr) 2025-11-21
AU2025234277A1 (en) 2025-10-16
EP4631505A3 (fr) 2025-12-10
IL283860B2 (en) 2025-10-01
KR20250103803A (ko) 2025-07-07
RS67216B1 (sr) 2025-10-31
KR102828472B1 (ko) 2025-07-03
PT3894012T (pt) 2025-09-25
CR20210375A (es) 2021-08-18
EP4631505A2 (fr) 2025-10-15
FI3894012T3 (fi) 2025-09-18
MA54458B1 (fr) 2025-09-30
CL2021001537A1 (es) 2022-02-04
PL3894012T3 (pl) 2026-01-05
IL283860B1 (en) 2025-06-01
US20230029213A1 (en) 2023-01-26
TW202039440A (zh) 2020-11-01
DK3894012T3 (da) 2025-09-15
TWI852963B (zh) 2024-08-21
LT3894012T (lt) 2025-10-10
PH12021551356A1 (en) 2021-12-06
JP2024038167A (ja) 2024-03-19
US12017995B2 (en) 2024-06-25
GEP20247596B (en) 2024-02-26
IL320433A (en) 2025-06-01
IL283860A (en) 2021-07-29
JP2026031599A (ja) 2026-02-24
AU2019395419A1 (en) 2021-07-01
AU2019395419B2 (en) 2025-06-26
SG11202105949RA (en) 2021-07-29
PE20211757A1 (es) 2021-09-07
ZA202103844B (en) 2024-11-27
US20240300897A1 (en) 2024-09-12
KR20210102381A (ko) 2021-08-19
TW202519513A (zh) 2025-05-16

Similar Documents

Publication Publication Date Title
MA54458A (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
MA53226A (fr) Sel et formes cristallines d'omecamtiv mecarbil
MA54526A (fr) NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta
EP3924352A4 (fr) Formes cristallines d'un inhibiteur rsk
EP3947361A4 (fr) Sel et forme cristalline d'un inhibiteur de fak
EP3870178A4 (fr) Formes cristallines d'inhibiteurs de mnk
EP3825309A4 (fr) Sel d'inhibiteur de lsd1 et polymorphe de celui-ci
MA52493A (fr) Sels d'un inhibiteur de fgfr
MA51066A (fr) Inhibiteurs d'intégrine
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
MA55614A (fr) Formes cristallines d'inhibiteur de pyridazinone trpc
MA55801A (fr) Formes solides d'un inhibiteur de glyt1
EP3870181A4 (fr) Formes cristallines d'un inhibiteur d'alk2
EP3856164A4 (fr) Formes morphiques d'inhibiteurs du facteur d du complément
EP3619208C0 (fr) Formes cristallines d'un composé inhibiteur de jak
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3897660A4 (fr) Nouvelles formes cristallines d'un composé de nrtti
MA54638A (fr) Formes cristallines d'un stimulateur de sgc
EP3873463A4 (fr) Sels cristallins d'un inhibiteur de la kallicréine plasmatique
MA53546A (fr) Nouvelles formes salines de chlorhydrate d'un inhibiteur de kinase à structure sulfamide
MA54541A (fr) Formes cristallines et salines d'un composé organique et compositions pharmaceutiques associées
EP3996707A4 (fr) Formes cristallines d'inhibiteurs de la kallicréine plasmatique
EP3849964A4 (fr) Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate